Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients

Metformin, the drug of choice in the treatment of type 2 diabetes mellitus (DM2), in addition to aspirin (ASA), the drug prescribed for cardioprotection of diabetic and non‐diabetic patients, have an inhibitory effect on cancer cell survival. The present population‐based study conducted in the province of Trieste (Italy), aimed to investigate the prevalence of DM2 in patients with colorectal adenocarcinoma (CRC) and survival for CRC in diabetic and nondiabetic patients. All permanent residents diagnosed with a CRC between 2004 and 2007 were ascertained through the regional health informa‐ tion system. CRC‐speci c and relative survival probabilities were computed for each group of patients de ned by CRC stage, presence or absence of DM2 treated with metformin, and presence or absence of daily ASA therapy. A total of 515 CRC patients without DM2 and 156 with DM2 treated with metformin were enrolled in the study. At the time of CRC diagnosis, 71 (14%) nondiabetic and 39 (25%) diabetic patients were taking ASA daily. The five‐year relative survival for stage III CRC was 101% [95% con dence interval (CI)=76‐126] in the 18 patients with DM2 treated with metformin and ASA, 55% (95% CI=31‐78) in the 23 without DM2 treated with ASA, 55% (95% CI=45‐65) in the 150 without DM2 not taking ASA, and 29% (95% CI=13‐45) in the 43 with DM2 treated with metformin, however not with ASA. The ndings support the hypothesis of a possible inhibitory effect of metformin and ASA on CRC cells. Randomized controlled trials are required to verify this hypothesis.